FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023591716> ?p ?o ?g. }

• W2023591716 endingPage "660" @default.
• W2023591716 startingPage "653" @default.
• W2023591716 abstract "The prognosis of patients with refractory/relapsed acute myelogenous leukemia (rAML) is poor. Recent studies have shown that more transplant centers are choosing allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for recipients, even with a higher leukemia burden. The purpose of the present study is to evaluate the outcome of rAML patients undergoing allo-PBSCT and to determine whether the disease status can predict the post-transplantation survival. The outcome of 58 patients (median age, 34 years; range, 14 to 52) with rAML who underwent allo-PBSCT in our institution from January 2000 until September 2011 was retrospectively studied. Thirty-three patients had complete remission (CR) before PBSCT, whereas 25 patients had no remission. Donors were matched related (31 patients) and unrelated (27 patients). Reduced-intensity conditioning was used for 18 patients with rAML, and myeloablative conditioning was used for others. Sixty-six consecutive non-rAML patients (median age, 33 years; range, 15 to 51) who received an allo-PBSCT at the same period were used as a control. Full donor-type engraftment was achieved in all patients. After a median follow-up of 61 months, the 5-year overall survival of rAML patients was 54.21% ± 7.06%, which was lower than non-rAML patients (71.82% ± 6.4%, P = .0386). However, the 5-year event-free survival for rAML and non-rAML patients had no statistical significance (53.54% ± 6.87% versus 62.07% ± 6.78%, P = .2626). The 5-year overall survival between rAML patients who had CR and no remission before PBSCT was 56.06% ± 9.2% and 51.85% ± 10.83%, respectively (P = .6408). These data demonstrate that allo-PBSCT is a promising and safe choice for the treatment of rAML, and the results were partially due to the rapid tapering of immunosuppressants in the early stage after PBSCT and prophylactic donor lymphocyte infusion. Meanwhile, the patients who did not achieve CR before PBSCT could also benefit from allo-PBSCT." @default.
• W2023591716 created "2016-06-24" @default.
• W2023591716 creator A5010479652 @default.
• W2023591716 creator A5028948842 @default.
• W2023591716 creator A5034579434 @default.
• W2023591716 creator A5036687874 @default.
• W2023591716 creator A5037989560 @default.
• W2023591716 creator A5042822012 @default.
• W2023591716 creator A5062370040 @default.
• W2023591716 creator A5066243142 @default.
• W2023591716 creator A5075913282 @default.
• W2023591716 creator A5076987233 @default.
• W2023591716 creator A5086328096 @default.
• W2023591716 creator A5087161790 @default.
• W2023591716 date "2013-04-01" @default.
• W2023591716 modified "2023-10-09" @default.
• W2023591716 title "Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden" @default.
• W2023591716 cites W1530764705 @default.
• W2023591716 cites W1564173940 @default.
• W2023591716 cites W165546792 @default.
• W2023591716 cites W1836187494 @default.
• W2023591716 cites W193514409 @default.
• W2023591716 cites W1965974612 @default.
• W2023591716 cites W1973392550 @default.
• W2023591716 cites W1986221562 @default.
• W2023591716 cites W1996903818 @default.
• W2023591716 cites W2000139755 @default.
• W2023591716 cites W2000291272 @default.
• W2023591716 cites W2002297224 @default.
• W2023591716 cites W2002984735 @default.
• W2023591716 cites W2013303840 @default.
• W2023591716 cites W2020304926 @default.
• W2023591716 cites W2022530052 @default.
• W2023591716 cites W2023014438 @default.
• W2023591716 cites W2026413523 @default.
• W2023591716 cites W2036961312 @default.
• W2023591716 cites W2042057994 @default.
• W2023591716 cites W2048306988 @default.
• W2023591716 cites W2050345519 @default.
• W2023591716 cites W2054433465 @default.
• W2023591716 cites W2055690659 @default.
• W2023591716 cites W2056158070 @default.
• W2023591716 cites W2073903374 @default.
• W2023591716 cites W2075154508 @default.
• W2023591716 cites W2077684036 @default.
• W2023591716 cites W2082261439 @default.
• W2023591716 cites W2094009473 @default.
• W2023591716 cites W2112218072 @default.
• W2023591716 cites W2113899987 @default.
• W2023591716 cites W2116858301 @default.
• W2023591716 cites W2117034501 @default.
• W2023591716 cites W2125080520 @default.
• W2023591716 cites W2127080762 @default.
• W2023591716 cites W2137294407 @default.
• W2023591716 cites W2138407409 @default.
• W2023591716 cites W2146099606 @default.
• W2023591716 cites W2155514224 @default.
• W2023591716 cites W2164078870 @default.
• W2023591716 cites W2164277940 @default.
• W2023591716 cites W2170758748 @default.
• W2023591716 cites W2185978763 @default.
• W2023591716 cites W2337680764 @default.
• W2023591716 cites W2586520356 @default.
• W2023591716 cites W4238829088 @default.
• W2023591716 cites W4244675750 @default.
• W2023591716 doi "https://doi.org/10.1016/j.bbmt.2013.01.015" @default.
• W2023591716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23353118" @default.
• W2023591716 hasPublicationYear "2013" @default.
• W2023591716 type Work @default.
• W2023591716 sameAs 2023591716 @default.
• W2023591716 citedByCount "31" @default.
• W2023591716 countsByYear W20235917162014 @default.
• W2023591716 countsByYear W20235917162015 @default.
• W2023591716 countsByYear W20235917162016 @default.
• W2023591716 countsByYear W20235917162017 @default.
• W2023591716 countsByYear W20235917162018 @default.
• W2023591716 countsByYear W20235917162019 @default.
• W2023591716 countsByYear W20235917162020 @default.
• W2023591716 countsByYear W20235917162021 @default.
• W2023591716 countsByYear W20235917162022 @default.
• W2023591716 countsByYear W20235917162023 @default.
• W2023591716 crossrefType "journal-article" @default.
• W2023591716 hasAuthorship W2023591716A5010479652 @default.
• W2023591716 hasAuthorship W2023591716A5028948842 @default.
• W2023591716 hasAuthorship W2023591716A5034579434 @default.
• W2023591716 hasAuthorship W2023591716A5036687874 @default.
• W2023591716 hasAuthorship W2023591716A5037989560 @default.
• W2023591716 hasAuthorship W2023591716A5042822012 @default.
• W2023591716 hasAuthorship W2023591716A5062370040 @default.
• W2023591716 hasAuthorship W2023591716A5066243142 @default.
• W2023591716 hasAuthorship W2023591716A5075913282 @default.
• W2023591716 hasAuthorship W2023591716A5076987233 @default.
• W2023591716 hasAuthorship W2023591716A5086328096 @default.
• W2023591716 hasAuthorship W2023591716A5087161790 @default.
• W2023591716 hasBestOaLocation W20235917161 @default.
• W2023591716 hasConcept C121332964 @default.
• W2023591716 hasConcept C126322002 @default.
• W2023591716 hasConcept C141071460 @default.

• next